PubMed:16445950 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":100},"obj":"Sentence"},{"id":"T2","span":{"begin":101,"end":204},"obj":"Sentence"},{"id":"T3","span":{"begin":205,"end":357},"obj":"Sentence"},{"id":"T4","span":{"begin":358,"end":604},"obj":"Sentence"},{"id":"T5","span":{"begin":605,"end":746},"obj":"Sentence"},{"id":"T6","span":{"begin":747,"end":854},"obj":"Sentence"},{"id":"T7","span":{"begin":855,"end":1050},"obj":"Sentence"},{"id":"T8","span":{"begin":1051,"end":1377},"obj":"Sentence"},{"id":"T9","span":{"begin":1378,"end":1593},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":100},"obj":"Sentence"},{"id":"T2","span":{"begin":101,"end":204},"obj":"Sentence"},{"id":"T3","span":{"begin":205,"end":357},"obj":"Sentence"},{"id":"T4","span":{"begin":358,"end":604},"obj":"Sentence"},{"id":"T5","span":{"begin":605,"end":746},"obj":"Sentence"},{"id":"T6","span":{"begin":747,"end":854},"obj":"Sentence"},{"id":"T7","span":{"begin":855,"end":1050},"obj":"Sentence"},{"id":"T8","span":{"begin":1051,"end":1377},"obj":"Sentence"},{"id":"T9","span":{"begin":1378,"end":1593},"obj":"Sentence"}],"text":"The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.\nThe increased pro-inflammatory cytokine production was previously observed in Alzheimer's disease (AD). We sought to explore whether acetylcholinesterase inhibitor (AChEI) therapy ameliorates clinical symptoms in AD through down-regulation of inflammation. Expression and release of monocyte chemotactic protein-1 (MCP-1), a positive regulator of Th2 differentiation, and interleukin (IL)-4, an anti-inflammatory cytokine from peripheral blood mononuclear cells (PBMC) in AD patients, were investigated. PBMC were purified from AD patients at time of enrollment (T0) and after 1 month of treatment with AChEI (T1) and from healthy controls (HC). Supernatants were analyzed for cytokine levels by ELISA methods. mRNA expression were determined by RT-PCR. Expression and production of MCP-1 and IL-4 were significantly increased in AD subjects under therapy with the AChEI Donepezil, compared to the same AD patients at time of enrollment (P \u003c 0.001). Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. The different amounts of MCP-1 and IL-4 observed might reflect the different states of activation and/or responsiveness of PBMC, that in AD patients could be kept in an activated state by pro-inflammatory cytokines."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":1245,"end":1250},"obj":"gene:6347"},{"id":"T1","span":{"begin":1366,"end":1368},"obj":"disease:C0002395"},{"id":"T2","span":{"begin":1255,"end":1259},"obj":"gene:3565"},{"id":"T3","span":{"begin":1366,"end":1368},"obj":"disease:C0002395"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.\nThe increased pro-inflammatory cytokine production was previously observed in Alzheimer's disease (AD). We sought to explore whether acetylcholinesterase inhibitor (AChEI) therapy ameliorates clinical symptoms in AD through down-regulation of inflammation. Expression and release of monocyte chemotactic protein-1 (MCP-1), a positive regulator of Th2 differentiation, and interleukin (IL)-4, an anti-inflammatory cytokine from peripheral blood mononuclear cells (PBMC) in AD patients, were investigated. PBMC were purified from AD patients at time of enrollment (T0) and after 1 month of treatment with AChEI (T1) and from healthy controls (HC). Supernatants were analyzed for cytokine levels by ELISA methods. mRNA expression were determined by RT-PCR. Expression and production of MCP-1 and IL-4 were significantly increased in AD subjects under therapy with the AChEI Donepezil, compared to the same AD patients at time of enrollment (P \u003c 0.001). Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. The different amounts of MCP-1 and IL-4 observed might reflect the different states of activation and/or responsiveness of PBMC, that in AD patients could be kept in an activated state by pro-inflammatory cytokines."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"16445950-2#29#49#gene43","span":{"begin":234,"end":254},"obj":"gene43"},{"id":"16445950-2#109#111#diseaseC0002395","span":{"begin":314,"end":316},"obj":"diseaseC0002395"},{"id":"16445950-6#29#34#gene6347","span":{"begin":884,"end":889},"obj":"gene6347"},{"id":"16445950-6#76#78#diseaseC0002395","span":{"begin":931,"end":933},"obj":"diseaseC0002395"},{"id":"16445950-7#204#208#gene3565","span":{"begin":1255,"end":1259},"obj":"gene3565"},{"id":"16445950-7#315#317#diseaseC0002395","span":{"begin":1366,"end":1368},"obj":"diseaseC0002395"}],"relations":[{"id":"29#49#gene43109#111#diseaseC0002395","pred":"associated_with","subj":"16445950-2#29#49#gene43","obj":"16445950-2#109#111#diseaseC0002395"},{"id":"29#34#gene634776#78#diseaseC0002395","pred":"associated_with","subj":"16445950-6#29#34#gene6347","obj":"16445950-6#76#78#diseaseC0002395"},{"id":"204#208#gene3565315#317#diseaseC0002395","pred":"associated_with","subj":"16445950-7#204#208#gene3565","obj":"16445950-7#315#317#diseaseC0002395"}],"text":"The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.\nThe increased pro-inflammatory cytokine production was previously observed in Alzheimer's disease (AD). We sought to explore whether acetylcholinesterase inhibitor (AChEI) therapy ameliorates clinical symptoms in AD through down-regulation of inflammation. Expression and release of monocyte chemotactic protein-1 (MCP-1), a positive regulator of Th2 differentiation, and interleukin (IL)-4, an anti-inflammatory cytokine from peripheral blood mononuclear cells (PBMC) in AD patients, were investigated. PBMC were purified from AD patients at time of enrollment (T0) and after 1 month of treatment with AChEI (T1) and from healthy controls (HC). Supernatants were analyzed for cytokine levels by ELISA methods. mRNA expression were determined by RT-PCR. Expression and production of MCP-1 and IL-4 were significantly increased in AD subjects under therapy with the AChEI Donepezil, compared to the same AD patients at time of enrollment (P \u003c 0.001). Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. The different amounts of MCP-1 and IL-4 observed might reflect the different states of activation and/or responsiveness of PBMC, that in AD patients could be kept in an activated state by pro-inflammatory cytokines."}